Impact of Delayed Adoption of Novel Atrial Fibrillation Treatments
More rapid adoption of newly approved nonvalvular atrial fibrillation treatments was associated with reduced stroke rates and high cost savings. Managed care organizations should consider how delays in the uptake of innovative medications impact health and economic outcomes.
Authors
- Jason Shafrin (ORCID: https://orcid.org/0000-0001-8444-5979)
- Anastasia G. Daifotis
- Jae‐Hong Kim (ORCID: https://orcid.org/0000-0002-8019-0208)
- HE Jinghua
- Jeremy Nighohossian
Institutions
- Center for the Study of Healthcare Provider Behavior (US)
Publication Details
- Journal
- The American Journal of Managed Care
- Published
- 2024-12-01
- DOI
- https://doi.org/10.37765/ajmc.2024.89639
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 2.26